Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
243.47
-4.06 (-1.64%)
At close: Jul 20, 2026, 4:00 PM EDT
243.01
-0.46 (-0.19%)
Pre-market: Jul 21, 2026, 4:37 AM EDT
Jazz Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 20 analysts polled by S&P Global, Jazz Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $263.1. The average 1-year stock price forecast is 8.06% higher than the current stock price, while the lowest is $196 (-19.50%) and the highest is $307 (+26.09%).
Price Target: $263.1 (+8.06%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Jazz Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 10 | 10 | 11 |
| Buy | 5 | 5 | 6 | 7 | 7 | 7 |
| Hold | 2 | 2 | 2 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 17 | 19 | 19 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Canaccord Genuity | Buy Initiates $290 | Buy | Initiates | $290 | +19.11% | Jul 16, 2026 |
| Wells Fargo | Wells Fargo | Buy Reiterates $265 → $285 | Buy | Reiterates | $265 → $285 | +17.06% | Jul 14, 2026 |
| Barclays | Barclays | Buy Maintains $253 → $260 | Buy | Maintains | $253 → $260 | +6.79% | Jul 14, 2026 |
Unknown Analyst Jefferies No rating | Jefferies | Buy Maintains $265 → $282 | Buy | Maintains | $265 → $282 | +15.83% | Jul 13, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jul 10, 2026 |
Financial Forecast
Revenue This Year
4.51B
from 4.27B
Increased by 5.64%
Revenue Next Year
4.83B
from 4.51B
Increased by 7.20%
EPS This Year
25.31
from 8.38
Increased by 202.01%
EPS Next Year
25.72
from 25.31
Increased by 1.64%
EPS and Forward PE are based on non-GAAP adjusted numbers.